Pro-active Genetic Testing in Kidney Transplant Patients
January 25, 2026 updated by: Girish K. Mour, Mayo Clinic
The purpose of this study is to determine the prevalence of genetic mutations that increase the risk of cancer and other medically actionable diseases in kidney transplant patients and to assess the impact of genetic testing on subsequent surveillance for cancer.
Study Overview
Status
Active, not recruiting
Conditions
Intervention / Treatment
Study Type
Observational
Enrollment (Actual)
177
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Arizona
-
Scottsdale, Arizona, United States, 85259
- Mayo Clinic Arizona
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 99 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Sampling Method
Non-Probability Sample
Study Population
Participants will be identified internally to Mayo Clinic Arizona via the kidney transplant program within one-year post transplant.
Description
Inclusion Criteria:
- Post transplant Kidney and Kidney Pancreas recipients.
Exclusion Criteria:
- Simultaneous Liver Kidney Transplant.
- Simultaneous Heart Kidney Transplant.
- Non renal transplant history.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
Kidney Transplants
Kidney transplant patients who are within one-year post transplant.
|
This panel covers cardiomyopathy genes, and cancer genes.
The results of this panel are reported as Positive (pathogenic or likely pathogenic mutation identified in one or more genes) or Negative (no pathogenic/likely pathogenic mutations identified).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Genetic mutations of cancer
Time Frame: 1 year
|
Number of subjects to have genetic mutations of cancer in kidney transplant patients receiving care at Mayo Clinic Arizona
|
1 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Develop a Biorepository
Time Frame: 1 year
|
Create a biorepository based on whole exome sequencing and clinical data for future analysis
|
1 year
|
|
The impact of genetic testing
Time Frame: 1 year
|
Current guidelines for cancer screening have limitations, as its mostly age based. Immunosuppression can lead to a increased risk of cancer in the kidney transplant population. By utilizing a multi gene panel we'll look for the number subjects with positive findings and see how recommendations of care change vs standard of care as recommended by the National Comprehensive Cancer Network (NCCN). Genetic testing and family history may change the practice regarding cancer screening in subjects undergoing kidney transplant evaluation. |
1 year
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Genetic mutations of cardiomyopathy
Time Frame: 1 year
|
Prevalence of genetic mutations for cardiomyopathies in kidney transplant recipients
|
1 year
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Girish Mour, MD, Mayo Clinic
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
March 28, 2022
Primary Completion (Estimated)
March 1, 2037
Study Completion (Estimated)
March 1, 2038
Study Registration Dates
First Submitted
March 11, 2022
First Submitted That Met QC Criteria
March 25, 2022
First Posted (Actual)
March 28, 2022
Study Record Updates
Last Update Posted (Actual)
January 27, 2026
Last Update Submitted That Met QC Criteria
January 25, 2026
Last Verified
January 1, 2026
More Information
Terms related to this study
Other Study ID Numbers
- 21-009697
- NCI-2022-02382 (Registry Identifier: CTRP (Clinical Trials Reporting Program))
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.